archive-au.com » AU » T » TRADERDEALER.COM.AU

Total: 417

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • Novogen | Online Stockmarket Trading Update
    rights to all of its drug candidates including ME 143 and ME 344 The company s intellectual property portfolio now includes 15 issued US patents at least 12 additional US patent applications and more than 70 issued foreign patents and 50 foreign patent applications Marshall Edwards Inc is a San Diego based oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism Novogen Limited NRT is an Australian biotechnology company based in Sydney Australia Novogen conducts research and development on oncology therapeutics through its subsidiary Marshall Edwards Inc and is developing glucan technology through its subsidiary Glycotex Inc www novogen com Tags Cancer treatment Marshall Edwards Novogen NRT Patent Granted Posted in ASX Company News No Comments ASX Company News Novogen Secures Cancer Treatment Patent Thursday December 22nd 2011 Novogen NRT subsidiary Marshall Edwards Inc an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism announced today that the US Patent and Trademark Office has issued a new patent covering a number of the company s isoflavone based compounds including lead oncology drug candidates ME 143 and ME 344 and their pharmaceutical compositions The patent is estimated to provide protection until March 2027 This patent represents another important milestone in our efforts to develop our lead drug candidates into valuable treatment options for patients with cancer said Daniel P Gold PhD President and Chief Executive Officer of Marshall Edwards Furthermore this demonstrates our commitment to further strengthening the intellectual property portfolio we acquired earlier this year which will be essential for partnering any of our drug candidates and enhancing shareholder value Marshall Edwards completed the acquisition of its isoflavone based intellectual property portfolio including worldwide rights to lead oncology drug candidates ME 143 and ME 344 from Novogen Limited in May 2011 The portfolio now includes 11 issued US patents at least 14 US patent applications at least 40 issued foreign patents and at least 80 foreign patent applications Marshall Edwards Inc is a San Diego based oncology company focused on the clinical development of novel anti cancer therapeutics The company s lead programs focus on two families of small molecules that result in the inhibition of tumour cell metabolism Novogen Limited NRT is an Australian biotechnology company based in Sydney Australia Novogen conducts research and development on oncology therapeutics through its subsidiary Marshall Edwards Inc and is developing glucan technology through its subsidiary Glycotex Inc www novogen com http www traderdealer com au Fundamentals nrt Tags Cancer Cures Cancer treatment Marshall Edwards Novogen NRT Patent Granted Posted in ASX Company News No Comments ASX Company News Novogen Enters Cancer Research Joint Venture With Ausio Pharmaceuticals Monday October 31st 2011 Marshall Edwards Inc an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism a subsidiary of Novogen NRT and Ausio Pharmaceuticals LLC a biopharmaceutical company focused on the development of safe and effective medicines for the aging population announced the signing of an exclusive royalty bearing licence agreement The

    Original URL path: http://blog.traderdealer.com.au/tag/novogen/ (2013-02-03)
    Open archived version from archive


  • Po Valley Energy Awarded Italian Offshore Exploration Licence | Online Stockmarket Trading Update
    producer and exploration company listed on the Australian Stock Exchange It has an expanding portfolio of hydrocarbon assets in northern Italy Po Valley holds 11 license areas encompassing 2 000 square kilometres and owns and operates two gas treatment plants Silllaro and Castello which provide the Company with steady cash flow www povalley com Tags Exploration Italian Licence Oil and Gas Po Valley Energy PVE ASX Company News pSivida Eye Disease Treatment Approved In Germany ASX Company News Novogen To Merge With Kai Medical This entry was posted on Monday July 30th 2012 at 11 23 am and is filed under ASX Company News You can follow any responses to this entry through the RSS 2 0 feed You can leave a response or trackback from your own site Leave a Reply Click here to cancel reply Name required Mail will not be published required Website RSS Feed Twitter Follow Us Sign up to our free weekly e newsletter Feel inspired Start trading Recent Post Markets Cap Best January Performance for Over a Decade Weekly Market Wrap The Covered Call Collar Part 3 1 of Options Trading for All Types of Market Environments Stock Market Analysis Markets Cap Best January for Over a Decade Stock Market Analysis Traders Take Profits Stock Market Analysis Markets Reach Bull Market Territory Stock Market Analysis US Markets Ease Near All Time Highs Markets Higher As Investors Play Catch Up Weekly Market Wrap Investing in 2013 continued Part 9 Stock Trading Tips for All Types of Market Environments Stock Market Analysis Markets Higher As Investors Play Catchup Stock Market Analysis Markets Cautious Ahead Of Chinese Data Archives February 2013 January 2013 December 2012 November 2012 October 2012 September 2012 August 2012 July 2012 June 2012 May 2012 April 2012 March 2012 February 2012 January 2012

    Original URL path: http://blog.traderdealer.com.au/2012/07/30/asx-company-news-po-valley-energy-awarded-italian-offshore-exploration-licence/ (2013-02-03)
    Open archived version from archive

  • Exploration | Online Stockmarket Trading Update
    au Tags Drilling Program Exploration Graphite Mining Monax Mining Posted in ASX Company News No Comments ASX Company News TNG Limited To Explore Toro Energy Property Friday April 13th 2012 TNG Limited TNG is pleased to announce that it has signed a Heads of Agreement with Australian uranium exploration and project development company Toro Energy Limited TOE providing TNG with the right to explore for all minerals except uranium within Toro Energy s EL 27115 EL 26848 and EL 27876 tenements The tenements lie immediately west of TNG s flagship Mount Peake Strategic Metals Project in the Northern Territory and are considered to be highly prospective for copper and nickel mineralisation based on previous exploration results The HOA will be known as the Walabanba Hills Project Under the terms of the HOA TNG must spend a total of A 500 000 on exploration activities within the first two years to earn a 51 interest in each of granted Exploration Licences EL s 27115 26848 and 27876 at which point a formal Joint Venture agreement between TNG and Toro will be signed subject to meeting conditions precedent TNG then has the right to increase its stake to 80 by spending a further A 1 5 million over the next five years Toro can then elect to retain assign or convert its remaining 20 interest to a 2 Net Smelter Royalty NSR TNG s Managing Director Mr Paul Burton said the new tenements were an exciting and highly prospective addition to the Company s copper exploration portfolio and strategy in the Northern Territory www tngltd com au Tags Exploration mining TNG TNG Limited TOE Toro Energy Posted in ASX Company News No Comments ASX Company News Tap Oil Sells Santos Interest In Exploration Permit Monday January 16th 2012 Tap Oil Limited TAP is pleased to announce that it has entered into an agreement with Santos Limited STO whereby Santos will acquire Tap s 8 2 interest in the WA 191 P exploration permit for a total cash payment of 21 7 million WA 191 P is located in the Carnarvon Basin offshore Western Australia and includes the proposed Fletcher Finucane oil development Santos will pay 18 0 million as consideration for the interest with the balance of 3 7 million representing a refund of cash already spent by Tap on the oil development A critical factor in the Fletcher Finucane development economics is the commercial terms under which the Mutineer Exeter facility will process the Fletcher Finucane oil When it became clear these terms could not be satisfactorily agreed between all participants negotiations led to the sale of Tap s interest to Santos Tap s Managing Director CEO Mr Troy Hayden said While we would have preferred to develop the project and generate a return from oil production this was not possible despite extensive negotiations with the Mutineer Exeter joint venture The proceeds from this sale bolster Tap s cash reserves ahead of a year of exciting exploration and development activity commencing

    Original URL path: http://blog.traderdealer.com.au/tag/exploration/ (2013-02-03)
    Open archived version from archive

  • Italian Licence | Online Stockmarket Trading Update
    fully evaluate structures within the two contiguous blocks and will help progress potentially attractive leads to drillable status The Po Valley region is the main gas production zone in Italy Po Valley Energy PVE is an oil and gas producer and exploration company listed on the Australian Stock Exchange It has an expanding portfolio of hydrocarbon assets in northern Italy Po Valley holds 11 license areas encompassing 2 000 square kilometres and owns and operates two gas treatment plants Silllaro and Castello which provide the Company with steady cash flow www povalley com Tags Exploration Italian Licence Oil and Gas Po Valley Energy PVE Posted in ASX Company News No Comments RSS Feed Twitter Follow Us Sign up to our free weekly e newsletter Feel inspired Start trading Recent Post Markets Cap Best January Performance for Over a Decade Weekly Market Wrap The Covered Call Collar Part 3 1 of Options Trading for All Types of Market Environments Stock Market Analysis Markets Cap Best January for Over a Decade Stock Market Analysis Traders Take Profits Stock Market Analysis Markets Reach Bull Market Territory Stock Market Analysis US Markets Ease Near All Time Highs Markets Higher As Investors Play Catch Up Weekly Market Wrap Investing in 2013 continued Part 9 Stock Trading Tips for All Types of Market Environments Stock Market Analysis Markets Higher As Investors Play Catchup Stock Market Analysis Markets Cautious Ahead Of Chinese Data Archives February 2013 January 2013 December 2012 November 2012 October 2012 September 2012 August 2012 July 2012 June 2012 May 2012 April 2012 March 2012 February 2012 January 2012 December 2011 November 2011 October 2011 September 2011 August 2011 July 2011 June 2011 May 2011 April 2011 March 2011 February 2011 January 2011 December 2010 November 2010 October 2010 September 2010 August 2010 July

    Original URL path: http://blog.traderdealer.com.au/tag/italian-licence/ (2013-02-03)
    Open archived version from archive

  • Po Valley Energy | Online Stockmarket Trading Update
    at the Castello field east of Milan This is a milestone for the Company and follows a successful civil and mechanical works program on site since July which was completed ahead of the scheduled four months to allow commissioning to commence this week Po Valley s Chief Executive Officer Mr Michael Masterman said today The key checkpoints over coming weeks will be on the field s pressure vessels a trial gas flow run and health and safety checks on the integrity of the surface plant Mr Masterman said With a successful commissioning program we anticipate Ministry approvals and first gas for commercial gas sales to be introduced into the pipeline in mid to late November Mr Masterman said Po Valley s second planned production contributor the Sillaro field east of Bologna is expected to commence commissioning work from January next year The majority of prefabricated equipment is now on site at Sillaro and mechanical assembly of the production plant will commence shortly Both fields are 100 owned by Po Valley www povalley com Tags New product Oil and Gas Po Valley Energy PVE Posted in ASX Company News No Comments Po Valley Energy Share Purchase Plan Thursday October 15th 2009 Po Valley Energy PVE announced on the 30 9 2009 that they would be conducting a Share Purchase Plan to raise additional capital The record date is the 15 10 2009 on which shareholders must own the share to participate in the SPP The closing date is 12 11 2009 Shares will be issued soon after A maximum of 15 000 can be purchased by each shareholder at 1 55 Discount 2 0 Liquidity Poor Profitability Ok Stability Poor www povalley com Note Discount is based on the closing price on the 14 October 2009 Tags Po Valley Energy PVE Share Purchase Plan SPP Posted in Share Purchase Plan SPP No Comments Po Valley Energy Share Purchase Plan Thursday October 15th 2009 Po Valley Energy PVE announced on the 30 9 2009 that they would be conducting a Share Purchase Plan to raise additional capital The record date is the 15 10 2009 on which shareholders must own the share to participate in the SPP The closing date is 12 11 2009 Shares will be issued soon after A maximum of 15 000 can be purchased by each shareholder at 1 55 Discount 2 0 Liquidity Poor Profitability Ok Stability Poor www povalley com Note Discount is based on the closing price on the 14 October 2009 For More Share Purchase Plans go to http blog mdsfinancial com au category share purchase plans To Buy Shares And Participate in Share Purchase Plans use Trader Dealer http www traderdealer com au Tags Po Valley Energy PVE Share Purchase Plan SPP Posted in Share Purchase Plan SPP No Comments RSS Feed Twitter Follow Us Sign up to our free weekly e newsletter Feel inspired Start trading Recent Post Markets Cap Best January Performance for Over a Decade Weekly Market Wrap The Covered

    Original URL path: http://blog.traderdealer.com.au/tag/po-valley-energy/ (2013-02-03)
    Open archived version from archive

  • PVE | Online Stockmarket Trading Update
    the Castello field east of Milan This is a milestone for the Company and follows a successful civil and mechanical works program on site since July which was completed ahead of the scheduled four months to allow commissioning to commence this week Po Valley s Chief Executive Officer Mr Michael Masterman said today The key checkpoints over coming weeks will be on the field s pressure vessels a trial gas flow run and health and safety checks on the integrity of the surface plant Mr Masterman said With a successful commissioning program we anticipate Ministry approvals and first gas for commercial gas sales to be introduced into the pipeline in mid to late November Mr Masterman said Po Valley s second planned production contributor the Sillaro field east of Bologna is expected to commence commissioning work from January next year The majority of prefabricated equipment is now on site at Sillaro and mechanical assembly of the production plant will commence shortly Both fields are 100 owned by Po Valley www povalley com Tags New product Oil and Gas Po Valley Energy PVE Posted in ASX Company News No Comments Po Valley Energy Share Purchase Plan Thursday October 15th 2009 Po Valley Energy PVE announced on the 30 9 2009 that they would be conducting a Share Purchase Plan to raise additional capital The record date is the 15 10 2009 on which shareholders must own the share to participate in the SPP The closing date is 12 11 2009 Shares will be issued soon after A maximum of 15 000 can be purchased by each shareholder at 1 55 Discount 2 0 Liquidity Poor Profitability Ok Stability Poor www povalley com Note Discount is based on the closing price on the 14 October 2009 Tags Po Valley Energy PVE Share Purchase Plan SPP Posted in Share Purchase Plan SPP No Comments Po Valley Energy Share Purchase Plan Thursday October 15th 2009 Po Valley Energy PVE announced on the 30 9 2009 that they would be conducting a Share Purchase Plan to raise additional capital The record date is the 15 10 2009 on which shareholders must own the share to participate in the SPP The closing date is 12 11 2009 Shares will be issued soon after A maximum of 15 000 can be purchased by each shareholder at 1 55 Discount 2 0 Liquidity Poor Profitability Ok Stability Poor www povalley com Note Discount is based on the closing price on the 14 October 2009 For More Share Purchase Plans go to http blog mdsfinancial com au category share purchase plans To Buy Shares And Participate in Share Purchase Plans use Trader Dealer http www traderdealer com au Tags Po Valley Energy PVE Share Purchase Plan SPP Posted in Share Purchase Plan SPP No Comments RSS Feed Twitter Follow Us Sign up to our free weekly e newsletter Feel inspired Start trading Recent Post Markets Cap Best January Performance for Over a Decade Weekly Market Wrap The Covered Call

    Original URL path: http://blog.traderdealer.com.au/tag/pve/ (2013-02-03)
    Open archived version from archive

  • pSivida Eye Disease Treatment Approved In Germany | Online Stockmarket Trading Update
    years pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems DurasertTM and BioSiliconTM ILUVIEN for the treatment of Diabetic Macular Edema DME which is licensed to Alimera Sciences Inc is pSivida s most advanced product candidate It has received marketing authorization for chronic DME considered insufficiently responsive to available therapies in the U K Austria France Germany and Portugal following a positive review by Austria France German Italy Portugal Spain and the U K under the Decentralized Procedure Marketing authorization in the remaining countries is anticipated in the coming months www psivida com Tags Biotechnology Eye Disease Treatment German Distribution Product Approval pSividia Corp PVA Stock Market Analysis European Markets Push Higher For Eighth Week ASX Company News Po Valley Energy Awarded Italian Offshore Exploration Licence This entry was posted on Monday July 30th 2012 at 11 20 am and is filed under ASX Company News You can follow any responses to this entry through the RSS 2 0 feed You can leave a response or trackback from your own site Leave a Reply Click here to cancel reply Name required Mail will not be published required Website RSS Feed Twitter Follow Us Sign up to our free weekly e newsletter Feel inspired Start trading Recent Post Markets Cap Best January Performance for Over a Decade Weekly Market Wrap The Covered Call Collar Part 3 1 of Options Trading for All Types of Market Environments Stock Market Analysis Markets Cap Best January for Over a Decade Stock Market Analysis Traders Take Profits Stock Market Analysis Markets Reach Bull Market Territory Stock Market Analysis US Markets Ease Near All Time Highs Markets Higher As Investors Play Catch Up Weekly Market Wrap Investing in 2013 continued Part 9 Stock Trading Tips

    Original URL path: http://blog.traderdealer.com.au/2012/07/30/asx-company-news-psivida-eye-disease-treatment-approved-in-germany/ (2013-02-03)
    Open archived version from archive

  • Biotechnology | Online Stockmarket Trading Update
    with a combined value of approximately US 3 4 billion In addition to acquiring Eclipse s world class assets Bionomics expansion into the US will enable it to benefit from a number of synergies as well as bring greater profile to its business development activities and accelerate its small molecule and antibody programs Bionomics BNO is a leading international biotechnology company which discovers and develops innovative therapeutics for cancer and diseases of the central nervous system Bionomics has small molecule product development programs in the areas of cancer anxiety Alzheimer s disease epilepsy and multiple sclerosis BNC105 which is undergoing clinical development for the treatment of cancer is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours BNC105 offers blockbuster potential if successfully developed A clinical program is also underway for the treatment of anxiety disorders and depression based on BNC210 a novel compound which stimulates neurite outgrowth BNC210 is partnered with Ironwood Pharmaceuticals www bionomics com au Tags acquisition Bionomics Biotechnology BNO Eclipse Therapeutics Posted in ASX Company News No Comments ASX Company News Pharmanet Receives NZ Patent For COX 2 Inhibitor Monday September 10th 2012 Pharmanet PNO advises that its wholly owned subsidiary Cambridge Scientific Pty Ltd CSPL has received the Letters Patent for New Zealand Patent No 573111 entitled Cox 2 Inhibitor The terms of the Letters Patent is for 20 years commencing from 27 April 2007 and expiring 27 April 2027 This patent describes the process of producing a selective inhibitor a form of non steroidal anti inflammatory drug directly targeting COX 2 an enzyme responsible for inflammation The Company expects that successful patent allowances will be repeated in other jurisdictions where corresponding applications are in advanced stages of examination Cambridge Scientific now holds granted patents for the Cox2 Inhibitor in Australia USA South Africa and New Zealand www pharmanet com au Tags Biotechnology Patent Granted Pharmanet PNO Posted in ASX Company News No Comments ASX Company News Atcor Medical Secures New Contract Tuesday August 14th 2012 AtCor Medical ACG the developer and marketer of the SphygmoCor system which measures central aortic blood pressures and arterial stiffness noninvasively announced that it has signed a contract to supply AtCor Medical s new SphygmoCor XCEL systems and clinical trial support services to a major international pharmaceutical company SphygmoCor XCEL measures brachial and central aortic blood pressure simultaneously and was launched by AtCor Medical in May 2012 The value of the contract is approximately US 1 1 million Duncan Ross CEO of AtCor Medical said We are pleased to have secured this contract and delighted the customer has decided to use the new XCEL system which greatly enhances ease of use while maintaining central aortic blood pressure waveform fidelity and data quality XCEL further consolidates AtCor Medical s gold standard position with both researchers and clinicians Our product quality is matched by our reputation as a highly reliable provider of clinical trial support services to the pharmaceutical sector AtCor Medical develops and markets products for the early detection of cardiovascular risk and management of cardiovascular disease Its technology allows researchers and clinicians to measure central blood pressure non invasively The company s SphygmoCor system visibly identifies the effects of reflected blood pressure in the central aortic pressure wave effects which cannot be detected with standard blood pressure monitoring More than 2 700 SphygmoCor systems are currently in use worldwide at major medical institutions research institutions and in various clinical trials with leading pharmaceutical companies The company s technology has been featured in over 600 peer reviewed studies published in leading medical journals www atcormedical com Tags ACG AtCor Medical Biotechnology Healthcare Posted in ASX Company News No Comments ASX Company News Novogen Acquires S BIO s HDAC Inhibitor Friday August 10th 2012 Novogen s NRT subsidiary MEI Pharma Inc an oncology company focused on the clinical development of novel therapies for the treatment of cancer announced that it has entered into a definitive asset purchase agreement with S BIO Pte Ltd a privately held biotechnology company pursuant to which MEI Pharma will acquire S BIO s exclusive worldwide rights to Pracinostat an investigational potential best in class oral histone deacetylase HDAC inhibitor We are excited to seize this opportunity to bolster our pipeline with a potential best in class late stage compound with activity against a validated target under favourable terms said Daniel P Gold PhD President and Chief Executive Officer of MEI Pharma The acquisition of Pracinostat broadens our potential addressable market in oncology with applications in both hematologic disorders and solid tumours We believe that the addition of this targeted small molecule to our existing portfolio of novel isoflavone based drug candidates ME 143 and ME 344 will significantly enhance shareholder value Pracinostat is a selective inhibitor of a group of enzymes called histone deacetylases HDAC HDACs belong to a larger set of proteins collectively known as epigenetic regulators that can alter gene expression by chemically modifying DNA or its associated chromosomal proteins Abnormal activity of these regulators is believed to play an important role in cancer and other diseases There are currently two HDAC inhibitors approved by the U S Food and Drug Administration FDA for the treatment of cutaneous T cell lymphoma one of which is also approved for the treatment of peripheral T cell lymphoma Pracinostat has been generally well tolerated in clinical testing of more than 150 patients with readily manageable side effects often associated with drugs of this class The most common adverse event all grades is fatigue Data from a Phase II clinical trial of oral Pracinostat showed evidence of single agent activity in heavily pre treated patients with intermediate or high risk myelofibrosis with two patients showing a clinical improvement These results are scheduled for publication in the September 2012 issue of Leukemia Research www novogen com Tags Acquisiton Biotechnology Cancer treatment Novogen NRT S BIO Posted in ASX Company News No Comments ASX Company News Healthlinx Sells Intellectual Property Assets Monday

    Original URL path: http://blog.traderdealer.com.au/tag/biotechnology/ (2013-02-03)
    Open archived version from archive



  •